Fady Farag, MD Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1801 16th St, Greeley, CO 80631 Phone: 970-810-3894 Fax: 970-810-3897 |
Dr. Thomas R Lininger, MD Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1675 18th Ave, Suite 3, Greeley, CO 80631 Phone: 970-347-5780 Fax: 970-347-5799 |
Dr. Joanne Monterroso Azpuru, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6767 29th St Fl 1, Greeley, CO 80634 Phone: 970-652-2780 Fax: 970-652-2797 |
Jose Ignacio Ruades Ninfea, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6767 29th St, Greeley, CO 80634 Phone: 970-652-2780 Fax: 970-652-2797 |
Dr. Michael D Stone, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1675 18th Ave, Suite 3, Greeley, CO 80631 Phone: 970-347-5780 Fax: 970-347-5799 |
News Archive
Researchers in the University of Georgia's Center for Tropical and Emerging Global Diseases have found that a more intensive, less frequent drug regimen with currently available therapeutics could cure the infection that causes Chagas disease, a potentially life-threatening illness affecting up to 300,000 people in the United States.
The first Monday after the holidays can be a depressing time for people coping with a post-holiday letdown and a type of depression triggered by short days called seasonal affective disorder.
If the Republicans have their way, the entire burden of deficit reduction will be placed on the elderly, the sick, children and working families. In the midst of a horrendous recession that is already causing severe pain for average Americans, this approach is morally grotesque. ... The Reid plan is bad. The constantly shifting plan by House Speaker John Boehner is much worse. ... Those cuts would mean drastic reductions in Social Security, Medicare and Medicaid.
Up to 10% of patients who are hospitalized or undergo surgery will experience acute kidney injury, and as many as 50% of patients in intensive care units will meet the criteria for AKI, the National Kidney Foundation has determined. Some of these patients will progress to kidney failure within months.
Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
› Verified 7 days ago